Time filter

Source Type

Vicenza, Italy

Saetti R.,Ospedale San Bortolo | Silvestrini M.,Ospedale Santa Chiara
European Archives of Oto-Rhino-Laryngology | Year: 2015

The purpose of this study was to assess the applicability and efficacy of ultrasonic instruments in laryngeal and pharyngeal endoscopic surgery. This article describes three cases of supraglottic laryngopharyngeal carcinoma transorally treated with the Harmonic forceps, which are indicative of our preliminary experience in this field. Based on our preliminary experience, we believe that the use of the ACE Harmonic forceps opens up very encouraging prospects in transoral endoscopic surgery of pharyngolaryngeal tumors and can potentially become a key instrument in this area. Given their different characteristics, we believe that ultrasonic instruments should be used not so much as an alternative to, but rather in addition to those traditionally used in pharyngolaryngeal endoscopic surgery and laser in particular. Finally, we hope that a more widespread use of these instruments in this surgical field may encourage manufacturers to solve the current technical limitations of miniaturization, thus designing and developing more precise and accurate instruments for this type of surgery. © 2015, Springer-Verlag Berlin Heidelberg. Source

Douketis J.,St. Josephs Healthcare Hamilton | Tosetto A.,Ospedale San Bortolo | Marcucci M.,University of Perugia | Baglin T.,University of Cambridge | And 6 more authors.
Annals of Internal Medicine | Year: 2010

Background: In patients with a first unprovoked venous thromboembolism (VTE), an elevated D-dimer level after anticoagulation is stopped is a risk factor for recurrent VTE. However, questions remain about the utility of measuring D-dimer in clinical practice. Purpose: To determine whether the timing of testing, patient age, and the cut point used to define a positive or negative result affect the ability of D-dimer testing to distinguish risk for recurrent disease. Data Sources: Comprehensive search of electronic databases (MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials) until July 2010, supplemented by reviewing conference abstracts and contacting content experts. Study Selection: 7 prospective studies that investigated an association between D-dimer, measured after stopping anticoagulation, and disease recurrence in patients with a first unprovoked VTE (proximal deep venous thrombosis, pulmonary embolism, or both). Data Extraction: Patient-level databases were obtained, transferred to a central database, checked, completed with further information provided by study investigators, and pooled into a single database. Data Synthesis: 1818 patients with a first unprovoked VTE were followed for a mean of 26.9 months (SD, 19.1). A study-stratified multivariate Cox regression model, which included patient age, sex, hormone therapy use at the time of the index event, body mass index, timing of postanticoagulation D-dimer testing, and inherited thrombophilia as possible confounders, indicated that the hazard ratio for D-dimer status (positive vs. negative) was 2.59 (95% CI, 1.90 to 3.52). Only male sex had a significant effect on risk for recurrent VTE independent of D-dimer status. The Cox regression model and the log-rank test confirmed that the risk for recurrent VTE was higher in patients with a positive D-dimer result than in those with a negative result, regardless of the timing of postanticoagulation D-dimer testing or patient age. No study- or assayspecific D-dimer effect was found, and reassessing the analysis after recoding data according to specific quantitative D-dimer cut points (500 μg/L and 250 μg/L) did not change the results. Limitations: Unmeasured variables could have affected the risk for recurrent VTE. The study population was predominantly white. Conclusion: In patients with a first unprovoked VTE who have their D-dimer level measured after stopping anticoagulation, the timing of D-dimer testing, patient age, and the assay cut point used do not affect the ability of D-dimer to distinguish patients with a higher or lower risk for recurrent VTE. Primary Funding Source: None. © 2010 American College of Physicians. Source

Lista G.,V. Buzzi Childrens Hospital | Boni L.,University of Florence | Scopesi F.,Neonatal ICU NICU | Mosca F.,University of Milan | And 12 more authors.
Pediatrics | Year: 2015

BACKGROUND: Studies suggest that giving newly born preterm infants sustained lung inflation abstract (SLI) may decrease their need for mechanical ventilation (MV) and improve their respiratory outcomes. METHODS: We randomly assigned infants born at 25 weeks 0 days to 28 weeks 6 days of gestation to receive SLI (25 cm H2O for 15 seconds) followed by nasal continuous positive airway pressure (nCPAP) or nCPAP alone in the delivery room. SLI and nCPAP were delivered by using a neonatal mask and a T-piece ventilator. The primary end point was the need for MV in the first 72 hours of life. The secondary end points included the need for respiratory supports and survival without bronchopulmonary dysplasia (BPD). RESULTS: A total of 148 infants were enrolled in the SLI group and 143 in the control group. Significantly fewer infants were ventilated in the first 72 hours of life in the SLI group (79 of 148 [53%]) than in the control group (93 of 143 [65%]); unadjusted odds ratio: 0.62 [95% confidence interval: 0.38-0.99]; P = .04). The need for respiratory support and survival without BPD did not differ between the groups. Pneumothorax occurred in 1% (n = 2) of infants in the control group compared with 6% (n = 9) in the SLI group, with an unadjusted odds ratio of 4.57 (95% confidence interval: 0.97-21.50; P = .06). CONCLUSIONS: SLI followed by nCPAP in the delivery room decreased the need for MV in the first 72 hours of life in preterm infants at high risk of respiratory distress syndrome compared with nCPAP alone but did not decrease the need for respiratory support and the occurrence of BPD. Copyright © 2015 by the American Academy of Pediatrics Source

Ronco C.,Ospedale San Bortolo
Blood Purification | Year: 2014

One of the key molecules involved in the pathogenesis of severe sepsis and septic shock is lipopolysaccharide (LPS) or endotoxin, which is a component of the cellular wall of Gram-negative bacteria. Clinical studies have shown that the level of circulating LPS is correlated with illness severity (APACHE II), the onset and amount of organ dysfunction (SOFA) and intensive care unit mortality. Many therapeutic strategies have attempted to neutralize the pathogenic activity of endotoxin in order to interrupt the progression of a septic state towards a worsened clinical framework, i.e. severe sepsis of septic shock. Over the past decades the role of extracorporeal hemoperfusion by means of polymyxin B-based cartridges (PMX-DHP) to bind and neutralize LPS from whole blood has increased in clinical relevance. This is due to an increasing number of studies confirming that a directed therapy of endotoxic shock could significantly influence the course of the septic cascade. This review will outline the meaning of the targeted approach to endotoxin, both highlighting the specific immunologic effect of endotoxin removal by polymyxin B and the evidence of clinical improvements following this kind of therapy in terms of recovery of organ function. © 2014 S. Karger AG, Basel. Source

Marongiu F.,University of Cagliari | Tosetto A.,Ospedale San Bortolo | Palareti G.,S. Orsola Malpighi University Hospital
Internal and Emergency Medicine | Year: 2012

In this review, we present some different and special conditions that are generally being treated with anticoagulants such as cerebral vein thrombosis (CVT), mesenteric vein thrombosis (MVT), Budd-Chiari syndrome (BCS), and Pulmonary Hypertension (PH) despite the lack of controlled clinical trials. While either low molecular weight heparins (LMWHs) or unfractioned heparin (UFH) are used in the acute phase of the first three conditions, the potential chronic use of warfarin in PH is controversial. What is not completely known in the management of CVT, MTV, and BCS is whether (a) LMWHs are similar to UFH in terms of efficacy and safety, and (b) a fibrinolytic drug could be employed in the acute phase. The timing at which warfarin should be started, and the duration of its employment are two additional crucial points that deserve to be examined. In the course of PH, the role of warfarin is controversial, but it could be employed after a careful balance of the hemorrhagic and thromboembolic risk. In conclusion, we tried to simplify the approach to this sometimes problematic task considering the available literature with the aim of providing some practical skills to be used by physicians in their daily clinical practice. Since it is improbable that in the future controlled clinical trials will be designed to find the optimal anti-thrombotic management of these conditions, we believe that a physician should be aware of the lack of solid data in the field but at the same time should always exert clinical judgment when considering an aggressive anticoagulant approach. The duration of oral anticoagulant treatment is left to the clinical judgment of the balance between the hemorrhagic and thrombotic risks in any single patient. © 2011 SIMI. Source

Discover hidden collaborations